Abstract
Several studies have demonstrated the importance of nicotinic mechanisms in the pathophysiology of neurodegenerative and cognitive disorders, warranting the search and development of novel nicotinic ligands as potential therapeutic agents. The present study was designed to assess whether the subtype-selective nicotinic acetylcholine receptor (nAChR) ligand SIB-1553A [(±)-4-{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride], with predominant agonist activity at β4 subunit-containing human nAChRs, and no activity at muscle nAChR subtypes, could enhance cognitive performance in rodents with a more desirable safety/tolerability profile as compared to the nonselective prototypic nAChR ligand nicotine. SIB-1553A was equi-efficacious to nicotine in improving working memory performance in scopolamine-treated mice as measured by increased alternation in a T-maze, and was more efficacious than nicotine in improving the baseline cognitive performance of aged mice. This effect on working memory was confirmed in a delayed nonmatching to place task using the eight-arm radial maze. SIB-1553A produced dose-dependent side effects (ie motor deficits and seizures), although these effects were observed at doses 12 to 640-fold above those required to increase cognitive performance. Overall, SIB-1553A was significantly less potent than nicotine in eliciting these undesirable effects. Thus, the subtype-selective profile of SIB-1553A appears to translate into a more efficacious and better tolerated nAChR ligand as compared to nicotine. In the present studies, cognitive enhancement induced by SIB-1553A was similar in magnitude to that produced by the clinically efficacious acetylcholinesterase inhibitor donepezil. Taken together, the present data confirm the importance of nAChR subtypes in modulating cognitive processes, and suggest that activation of nAChR subtypes by selective nAChR ligands may be a viable approach to enhance cognitive performance.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL (2000). Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99: 17–23.
Bartus RT, Dean III RL, Beer B, Lippa AS (1982). The cholinergic hypothesis of geriatric memory dysfunctions. Science 217: 408–417.
Benowitz NL (1986). Clinical pharmacology of nicotine. Ann Rev Med 37: 21–32.
Bontempi B, Whelan KT, Risbrough VB, Rao TS, Buccafusco JJ, Lloyd GK et al (2001). SIB-1553A, (±)-4-{[2-(1-methyl-2-pyrrolidinyl)ethyl]thio}phenol hydrochloride, a subtype-selective ligand for nicotine acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and non-human primates. J Pharmacol Exp Ther 299: 297–306.
Bryson HM, Benfield P (1997). Donepezil. Drugs Aging 10: 234–239.
Cho YH, Beracochea D, Jaffard R (1992). Differential effects of ibotenate lesions of the CA1 subfield of the hippocampus on a delayed non-matching-to-place task as a function of preoperative training in mice. Psychobiology 20: 261–269.
Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E (2001). Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49: 175–184.
Cullen KM, Halliday GM, Double KL, Brooks WS, Creasey H, Broe GA (1997). Cell loss in the nucleus basalis is related to regional cortical atrophy in Alzheimer's disease. Neuroscience 78: 641–652.
Dember WN, Fowler H (1958). Spontaneous alternation behavior. Psychol Bull 55: 412–427.
Dunn NR, Pearce GL, Shakir SA (2000). Adverse effects associated with the use of donepezil in general practice in England. J Psychopharmacol 14: 406–408.
Eid Jr CN, Rose GM (1999). Cognition enhancement strategies by ion channel modulation of neurotransmission. Curr Pharm** Des 5: 345–361.
Francis PT, Palmer AM, Snape M, Wilcock GK (1999). The cholinergic hypothesis of Alzheimer's disease: a review in progress. J Neurol Neurosurg Psychiatry 66: 135–147.
Gallagher M, Colombo PJ (1995). Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 5: 161–168.
Gevins A, Smith ME, McEvoy LK (2002). Tracking the cognitive pharmacodynamics of psychoactive substances with combinations of behavioral and neurophysiological measures. Neuropsychopharmacology 26: 27–39.
Giacobini E, Zhu XD, Williams E, Sherman KA (1996). The effect of the selective acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35: 205–211.
Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA et al (2000). Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 57: 94–99.
Gross CG, Chorover SL, Cohen SM (1965). Caudate, cortical hippocampal, and dorsal thalamic lesions in rats: alternation and Hebb–Williams maze performance. Neuropsychologia 3: 53–68.
Grutzendler J, Morris JC (2001). Cholinesterase inhibitors for Alzheimer's disease. Drugs 61: 41–52.
Hellstrom-Lindhal E, Moore H, Nordberg A (2000). Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 74: 777–784.
Hiramatsu M, Inoue K (2000). Improvement by low doses of nociceptin on scopolamine-induced impairment of learning and/or memory. Eur J Pharmacol 395: 149–156.
Imbimbo BP (2001). Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 15: 375–390.
Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992). Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108: 417–431.
Kaiser S, Wonnacott S (1998). Nicotinic receptor modulation of neurotransmitter release. In: Arneric SP, Brioni JD (eds). Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities. Wiley-Liss: New York. pp 141–159.
Krazem A, Borde N, Béracochéa D (2001). Effects of diazepam and β-CCM on working memory in mice: relationships with emotional reactivity. Pharmacol Biochem Behav 68: 235–244.
Lawrence AD, Sahakian BJ (1998). The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem Res 23: 787–794.
Levin ED, Simon B (1998). Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138: 217–230.
Lindstrom J (1997). Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol 15: 193–222.
Lloyd GK, Menzaghi F, Bontempi B, Suto C, Siegel R, Akong M et al (1998). The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci 62: 1601–1606.
Lloyd K, Menzaghi F, McClure D, Gautille T, Broome S, Rao T et al (1999). Neuronal nicotinic receptor agonists as potential therapeutuc agents for Alzheimer's disease. J Eur College Neuropsychopharmacol 9 (Suppl 5): S163.
Menzaghi F, McClure DE, Lloyd GK (1998). Subtype-selective nAChR agonists for the treatment of neurological disorders: SIB-1508Y and SIB-1553A. In: Arneric SP, Brioni JD (eds). Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities. Wiley-Liss: New York. pp 379–394.
Mihailescu S, Drucker-Colin R (2000). Nicotine and brain disorders. Acta Pharmacol Sin 21: 97–104.
Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA et al (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481–488.
Newhouse PA, Potter A, Kelton M, Corwin J (2001). Nicotinic treatment of Alzheimer's disease. Biol Psychiatry 49: 268–278.
Olton DS, Becker JT, Handelmann GE (1979). Hippocampus, space and memory. Behav Brain Sci 2: 313–365.
Packard MG, Hirsh R, White NM (1989). Differential effects of fornix and caudate nucleus lesions on two radial maze tasks: evidence for multiple memory systems. J Neurosci 9: 1465–1472.
Perry E, Court J, Goodchild R, Griffiths MM, Jaros E, Johnson M et al (1998). Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 105: 915–933.
Perry EK, Martin-Ruiz CM, Court JA (2001). Nicotinic receptor subtypes in human brain related to aging and dementia. Alcohol 24: 63–68.
Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1987). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2: 1457–1459.
Ragozzino ME, Arankowsky-Sandoval G, Gold PE (1994). Glucose attenuates the effect of combined muscarinic-nicotinic receptor blockade on spontaneous alternation. Eur J Pharmacol 256: 31–36.
Rezvani AH, Levin ED (2001). Cognitive effects of nicotine. Biol Psychiatry 49: 258–267.
Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998). Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study group. Arch Intern Med 158: 1021–1031.
Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX et al (2000). Galantamine is an allosterically potentiating ligand of the human alpha4/beta2nAChR. Acta Neurol Scand 176 Suppl: 68–73.
Schroder H, Giacobini E, Struble RG, Zilles K, Maelicke A (1991). Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 12: 259–262.
Schuck S, Bentue-Ferrer D, Kleinermans D, Reymann JM, Polard E, Gandon JM et al (2002). Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol 16: 57–65.
Shimohama S, Taniguchi T, Fujiwara M, Kameyama M (1986). Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 46: 288–293.
Sirviö J (1999). Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients. Gerontology 45: 3–14.
Stefani MR, Gold PE (2001). Intrahippocampal infusions of K-ATP channel modulators influence spontaneous alternation performance: relationships to acetylcholine release in the hippocampus. J Neurosci 21: 609–614.
Stone WS, Walser B, Gold SD, Gold PE (1991). Scopolamine- and morphine-induced impairments of spontaneous alternation performance in mice: reversal with glucose and with cholinergic and adrenergic agonists. Behav Neurosci 105: 264–271.
Tako A, Béracochéa DJ, Jaffard R (1988). Accelerated rate of forgetting of spatial information following mammillary body lesions in mice: effects of context change on retention-test performance. Psychobiology 16: 45–53.
Vernier JM, El-Abdellaoui H, Holsenback H, Cosford ND, Bleicher L, Barker G et al (1999). 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J Med Chem 42: 1684–1686.
Watkins SS, Koob GF, Markou A (2000). Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2: 19–37.
White HK, Levin ED (1999). Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 143: 158–165.
White NM, McDonald RJ (2002). Multiple parallel memory system in the brain of the rat. Neurobiol Learn Mem 77: 125–184.
Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL et al (1986). Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 371: 146–151.
Wilkinson DG (1999). The pharmacology of donepezil: a new treatment of Alzheimer's disease. Expert Opin Pharmacother 1: 121–135.
Wilson AL, Langley LK, Monkey J, Bauer T, Rottunda S, McFalls E et al (1995). Nicotine patches inAlzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 51: 509–514.
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G et al (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495.
Acknowledgements
Bruno Bontempi (BB) was supported in part by a grant from the Pôle Aquitaine Santé, Secteur Médicament (Pessac, France), and the Conseil Régional d'Aquitaine. BB is currently at the Laboratoire de Neurosciences Cognitives, UMR CNRS 5106, Avenue des Facultés, 33405 Talence (France).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bontempi, B., Whelan, K., Risbrough, V. et al. Cognitive Enhancing Properties and Tolerability of Cholinergic Agents in Mice: A Comparative Study of Nicotine, Donepezil, and SIB-1553A, a Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors. Neuropsychopharmacol 28, 1235–1246 (2003). https://doi.org/10.1038/sj.npp.1300150
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300150
Keywords
This article is cited by
-
The [3+2] cycloaddition reaction as an attractive way for the preparation of nicotine analogs (microreview)
Chemistry of Heterocyclic Compounds (2023)
-
Regio- and stereoselective synthesis of nitrofunctionalized 1,2-oxazolidine analogs of nicotine
Chemistry of Heterocyclic Compounds (2020)
-
Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease
Neurotherapeutics (2017)
-
In vitro and ex-vivo cellular antioxidant protection and cognitive enhancing effects of an extract of Polygonum minus Huds (Lineminus™) demonstrated in a Barnes Maze animal model for memory and learning
BMC Complementary and Alternative Medicine (2014)
-
Generation and Characterization of Humanized Mice Carrying COMT158 Met/Val Alleles
Neuropsychopharmacology (2014)
